Beacon Therapeutics secures $170m Series B funding led by Forbion for ophthalmic gene therapy development.
Beacon Therapeutics, a leading ophthalmic gene therapy company, has secured $170 million in Series B funding led by Forbion. Existing investors Syncona and Oxford Science Enterprises, along with new investors TCGX and Advent Life Sciences, also participated in the round. The funding aims to accelerate the development of Beacon's lead asset, AGTC-501, and its broader pipeline for treating blinding retinal diseases.
July 03, 2024
6 Articles